(Date)Apr 6 (Fri) – Apr 7 (Sat), 2012
(Venue) Hilton Fukuoka Sea Hawk Hotel, Fukuoka, Japan

Day 1: Apr 6, 2012

9:25 Opening Remarks Yoichi Nakanishi (President of WJOG, Kyushu University, Japan)

9:30 Plenary Session I: Combined Modality Therapy for Localized Diseases(150 minutes) Chair:Mitsuru Sasako (Hyogo College of Medicine, Japan) 　　　Yasumasa Nishimura (Kinki University Faculty of Medicine, Japan) Role of gefitinib/erlotinib as surgical adjuvant therapy (15 minutes) 　Hirohito Tada (Osaka City General Hospital, Japan) Perioperative chemotherapy for resectable gastric cancer (15 minutes) 　Takako Nakajima (St. Marianna University School of Medicine, Japan) Perioperative endocrine therapy for premenopausal breast cancer (START trial) (15 minutes) 　Takayuki Kinoshita (National Cancer Center Hospital) Neoadjuvant therapy for breast cancer (20 minutes) 　Sung-Bae Kim (Asan Medical Center, Korea) Changes in Rectal Cancer Management (20 minutes) 　Christopher Willett (Duke University, USA) Combined modality therapy for locally advanced lung cancer (20 minutes) 　James Chih-Hsin Yang (National Taiwan University, Taiwan) Discussion

12:00 Lunch

13:00 Keynote Address (60 minutes) Chair: Masahiro Fukuoka (Past-President of WJOG, Izumi Municipal Hospital, Japan) Transition from Empiric to Molecular-based and Personalized Therapy of Cancer: Non-small Cell　Lung Cancer (NSCLC) as a Model 　David Gandara (UC Davis Cancer Center, USA)

14:00 Plenary Session II: Biomarker driven studies (150 minutes) Chair:Junya Fukuoka (Toyama University, Japan) 　　　Hironobu Minami (Kobe University Hospital, Japan) BATTLE study (20 minutes) 　Ignacio Wistuba (UT MD Anderson Cancer Center, USA) Biobank in Japan (15 minutes) 　Kazuto Nishio (Kinki University School of Medicine, Japan) Why oncogene driven treatment strategy has not been so successful in GI cancer? (20 minutes) 　Sun Young Rha (Yonsei Cancer Center,Yonsei University, Korea) Disease subclassifiation in colorectal cancer: current state and challenges (20 minutes) 　Sabine Tejpar (University Hospital Gasthuisberg, Leuven, Belgium) Clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy in breast cancer (15 minutes) 　Yoshinori Ito (Cancer Insitute Hospital of JFCR, Japan） Rationale of ELTOP study (TBD) (15 minutes) 　Toshimi Takano (Toranomon Hospital, Japan) Discussion

16:40 Break

16:50 Organ Specific Breakout Session I (90 minute) Thoracic: ALK Lung Cancer Chair:Nagahiro Saijo (Kinki University School of Medicine, Japan) 　　　Nobuyuki Yamamoto (Shizuoka Cancer Center, Japan) Clinical trials (20 minutes) 　Keunchil Park (Samsung Medical Center, Korea) Title: Novel ALK Inhibitor (TBD) (15 minutes) 　Hiroshi Sakamoto (Chugai Pharmaceutical Co., LTD, Japan) Acuired resistance to ALK inhibitors (15 minutes) 　Takaaki Sasaki (Asahikawa Medical School, Japan) Diagnosis of ALK translocation (15 minutes) 　Yasushi Yatabe (Aichi Cancer Center, Japan) Discussion GI: New drugs in GI cancer for future Asian trial Chair:Chikashi Ishioka (Tohoku University School of Medicine, Japan) 　　　Narikazu Boku (St. Marianna University School of Medicine Hospital, Japan) Nimotuzumab ( 20 minutes) 　Yeul Hong Kim (Korea University, Korea) SOL and SOLA (15 minutes) 　Kentaro Yamazaki (Shizuoka Cancer Center, Japan) TAS-102 (15 minutes) 　Takayuki Yoshino (National Cancer Center Hospital East) Discussion Breast: Treatment Strategy for Early Breast Cancer by Biomarker and Multi-gene Assay Chair:Shigeru Imoto (Kyorin University Hospital, Japan) 　　　Hiroyoshi Doihara(Okayama University Hospital, Japan) Prognostic analysis for Japanese Breast Cancer Patients by MammaPrint (15 minutes) 　Makoto Ishitobi (Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan) Prognostic analysis for Japanese Breast Cancer Patients by Oncotype DX (15 minutes) 　Seigo Nakamura (Showa University, Japan) Biomarker study of Breast Cancer in Korea (20 minutes) 　Sung-Bae Kim（'Ulsan University, Asan Hospital, Korea） Oncotype DX predicts endocrine sensitivity in the post menopausal breast cancer (15 minutes) 　Norikazu Masuda (NHO Osaka National Hospital, Japan) Discussant 　Mark Pegram (University of Miami Hospital, USA) (15 minutes)

Day 2: Apr 7, 2012

8:00 Organ Specific Breakout SessionⅡ (80 minute) Thoracic: Overcoming acquired resistance of EGFR TKI Chair:Roman Thomas (Max-Plank Institute, Germany) 　　　Takashi Seto (NHO Kyushu Cancer Center, Japan) Molecular pathology of EGFR mutation and EGFR-TKi resistance. (20 minutes) 　Ignacio Wistuba (The University of Texas M.D. Anderson Cancer Center, USA) Resistance mechanism of EGFR-TKI (15 minutes) 　Hiromichi Ebi (Dana Farber Cancer Institute) Beyond EGFR-TKI based combination therapy for overcoming acquired resistance (15 minutes) 　Isamu Okamoto(Kinki University, School of Medicine, Japan) New generation of EGFR-TKI (20 minutes) 　James Chih-Hsin Yang (National Taiwan University, Taiwan) Discussion GI: New drugs in GI cancer for future Asian trial Chair:Yasuhide Yamada (National Cancer Center Hospital, Japan) 　　　Haruhiko Fukuda (National Cancer Center Hospital, Japan) REGATTA trial (15 minutes: TBD) 　Yukinori Kurokawa (Osaka university, Japan） START trial (20 minutes: TBD) 　Yeul Hong Kim (Korea University, Japan) SOS study: A platform for future collaboration in gastric cancer between Japan and Korea (35 minutes: TBD) 　Yoon-Koo Kang (Asan Medical Center, Korea) 　Eiji Baba (Kyushu University) Discussion Breast: New strategy for metastatic breast cancer treatment Chair:Hajime Abe (Shiga University of Medical Science Hospital, Japan) 　　　Kenjiro Aogi (NHO Shikoku Cancer Center)) Phase II study of Eribulin in Japan and EMBRACE study (TBD) (15 minutes) 　Nobuaki Sato (Nigata Cancer Center, Japan) Study of nab-paclitaxel in Japan (15 minutes) 　Kenji Tamura (National Cancer Center Hospital, Japan) SELECT study (15 minutes) 　Hirofumi Mukai (Natioal Cancer Research Center Hospital East, Japan) Discussion

9:20 Break

9:30 Plenary Session III: Novel therapeutics (140 minutes) Chair:Atsushi Otsu (National Cancer Center Hospital East, Japan) 　　　Koji Takeda (Osaka City General Hospital, Japan) New druggable targets in squamous cell carcinoma of the lung (20 minutes) 　Roman Thomas (Max-Plank Institute, Germany) Combination of novel targeted drugs involving the PI3K/AKT/mTOR pathway (15 minutes) 　Toshio Shimizu (Kinki University School of Medicine) Introduction to oncolytic virus therapy (10 minutes) 　Masato Abei (University of Tsukuba, Japan) Cancer-targeted, armed oncolytic vaccinia virus: Concepts and preclinical studies (15 minutes) 　Tae-Ho Hwang (Pusan National University, Korea) Cancer-targeted, armed oncolytic vaccinia virus: Advances in clinical trials (25 minutes) 　David Kirn (Jennerex Biotherapeutics, Inc, USA） Pertuzumab+trastuzumab in breast cancer (CREOPATRA stuy) (20 minutes) 　Mark Pegram(University of Miami Hospital, USA) Everolimus in combination with exemestane in the treatment of postmenopausal women with ER+ MBC(BOLERO-2 study)(15 minutes) 　Yoshinori Ito (Cancer Insitute Hospital of JFCR, Japan） Discussion

11:50 Break

12:05 Plenary Session IV : Role of Asia / WJOG studies: Present and 5 years from now (100 minutes) (Luncheon Session) Chair:Tomohide Tamura (National Cancer Center Hospital, Japan) 　　　Yoichi Nakanishi (President of WJOG, Kyushu University, Japan) WJOG studies in thoracic group (25 minutes) 　Kazuhiko Nakagawa (Kinki University, School of Medicine, Japan) 　Discussant: David Gandara (UC Davis Cancer Center, USA) (10 minutes) WJOG studies in GI group (20 minutes) 　Ichinosuke Hyodo (University of Tsukuba, Japan) 　Discussant: Yoon-Koo Kang (Asan Medical Center) (10 minutes) WJOG studies in breast group(15 minutes) 　Toshiaki Saeki (Saitama Medical University International Medical Center, Japan) 　Discussant: M Pegram (University of Miami Hospital, USA) (10 minutes) Expectation for WJOG 5 years from now (10 minutes) 　Keunchil Park (Samsung Medical Center, Korea)

13:45 Closing remarks (10 minutes) Tetsuya Mitsudomi (Chairperson, Scientific Committee, Aichi Cancer Center, Japan)